“Over the course of a year, we have learned how to treat patients with Covid-19 much better. Unfortunately, from the point of view of the real possibilities of treatment, we have not made great strides“. He explains it to time.news Salute, Massimo Galli, primary infectious disease specialist at the Sacco hospital in Milan and lecturer at the State University of the Lombard capital, who announces a study, of which he is the main author, sponsored by the Italian Society of Infectious and Tropical Diseases (Simit), aimed precisely at learning more about the effects of known therapies. It is studio Ammuravid (Adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for moderate Covid-19) which however – Galli complains – “we are struggling to start” for purely bureaucratic problems.
“The Ammuravid studio – he explains – is authorized and financed by Aifa. And yet struggling to leave because, despite the central authorizations, we have difficulties at the peripheral level. E’ a study on drugs already known to be active against the disease, such as the steroid, remdesivir, baricitinib. This is an experiment that should answer some questions about their effectiveness individually or in combination, in a certain phase of the disease “. But” to be able to do all this we have been fighting for several months. Italy is the country of rules and their rigidity. The problem is in always having myriads of cards ‘in place’, some of which are really redundant “.
Regarding remdesivir, first drug to be authorized to treat Covid 19, “it has been shown to be effective, in part, in patients in advanced stages of the disease. The goal is to see if in an intermediate phase it can have a different effectiveness“. For the start of the study” we should be able to recruit shortly. This is a very large trial. Once you start, it will take a few months to get the results. However, in the meantime, many patients that I fear we will have been treated well, given that we are at the beginning of the third wave “, concludes Galli.